Open AccessSurvivorship Care Provision for Patients With Hematologic Malignancies
Author(s) -
Raymond Javan Chan,
Alexandre Chan
Publication year - 2015
Publication title -
cancer nursing
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.79
H-Index - 76
eISSN - 1538-9804
pISSN - 0162-220X
DOI - 10.1097/ncc.0000000000000288
Subject(s) - medicine , survivorship curve , hematologic malignancy , psychosocial , cancer , multiple myeloma , quality of life (healthcare) , hematologic disease , population , disease , oncology , intensive care medicine , psychiatry , nursing , environmental health
This is an editorial that depicts the importance for developing more quality evidence to guide the survivorship care provision for patients with hematologic malignancies.\ud\udTreatments for hematologic malignancies are often complex and debilitating, with increased\udrisk of immune suppression and infections1. Some patients receive allogeneic stem cell\udtransplantation that often requires in-patient stay of several weeks and life-long medical\udfollow up. In recent years, advances in treatment regimens, and an aging population saw an\udincreasing number of patients living with a hematologic malignancies or surviving curative\udtherapy.2 The increased use of targeted therapies in hematologic malignancies (e.g.\udrituximab for non-Hodgkin lymphoma, bortezomib in multiple myeloma and imatinib in\udChronic Myelogenous Leukemia has also resulted in improved overall survival..